目的 探讨宁泌泰胶囊联合盐酸坦索罗辛缓释胶囊治疗良性前列腺增生症的临床疗效。方法 选取2018年6月—2020年3月在河南大学附属郑州颐和医院就诊的88例良性前列腺增生症患者作为本研究对象，按照随机数字表法分为对照组和治疗组，每组各44例。对照组口服盐酸坦索罗辛缓释胶囊，0.2 mg/次，1次/d。治疗组在对照组患者治疗的基础上口服宁泌泰胶囊，4粒/次，3次/d。两组患者连续治疗3个月。观察两组的疗效，比较两组患者残余尿量、前列腺体积、最大尿流率的变化及血清总前列腺特异抗原（tPSA）、胰岛素样生长因子-1（IGF-1）、转化生长因子β₁（TGF-β₁）的水平，对患者的病情严重程度采用前列腺症状评分（IPSS）进行评估。结果 治疗后，治疗组患者总有效率为93.18%，对照组总有效率为77.27%，两组比较差异有统计学意义（P<0.05）。治疗后，两组的残余尿量、前列腺体积显著降低，最大尿流率显著提高（P<0.05）；治疗后，治疗组的残余尿量、前列腺体积低于对照组，最大尿流率高于对照组（P<0.05）。治疗后，两组的tPSA、IGF-1、TGF-β₁显著降低（P<0.05）；治疗后治疗组的tPSA、IGF-1、TGF-β₁低于对照组（P<0.05）。治疗后，两组的IPSS评分显著降低，治疗组的IPSS评分较对照组降低的更明显，差异有统计学意义（P<0.05）。结论 宁泌泰胶囊联合盐酸坦索罗辛缓释胶囊治疗良性前列腺增生症具有较好的临床疗效，可减轻临床症状，调节tPSA、IGF-1、TGF-β₁的分泌。

Objective To explore the clinical effect of Ningmitai Capsules combined with Tamsulosin Hydrochloride Sustained Release Capsules in treatment of benign prostatic hyperplasia. Methods Patients (88 cases) with benign prostatic hyperplasia in Zhengzhou Yihe Hospital Affiliated to Henan University from June 2018 to March 2020 were randomly divided into control and treatment groups, and each group had 44 cases. Patients in the control group were po administered with Tamsulosin Hydrochloride Sustained Release Capsules, 0.2 mg/time, once daily. Patients in the treatment group were po administered with Ningmitai Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacies were evaluated, and residual urine volume, prostate volume, maximum urine flow rate, and the levels of tPSA, IGF-1, and TGF-β₁ in two groups were compared. The severity of the disease in two groups was evaluated by IPSS scores. Results After treatment, the total effective rate of the treatment group was 93.18%, and that of the control group was 77.27%, and there was difference between two groups (P<0.05). After treatment, the residual urine volume and prostate volume of two groups were significantly reduced, and the maximum urinary flow rate was significantly increased (P<0.05). After treatment, the residual urine volume and prostate volume of the treatment group were lower than those of the control group, and the maximum urinary flow rate of the treatment group was higher than that of the control group (P<0.05). After treatment, the levels of tPSA, IGF-1, and TGF-β₁ in two groups were significantly decreased (P<0.05). After treatment, the levels of tPSA, IGF-1, and TGF-β₁ in the treatment group were lower than those in the control group (P<0.05). After treatment, the IPSS score of two groups was significantly decreased, and the IPSS score of the treatment group was more significantly lower than that of the control group (P<0.05). Conclusion Ningmitai Capsules combined with Tamsulosin Hydrochloride Sustained Release Capsules has clinical curative effect in treatment of benign prostatic hyperplasia, can relieve clinical symptoms, and regulate the secretion of tPSA, IGF-1 and TGF-β₁, which has good clinical application value.

R983

河南省卫生健康科技英才海外研修工程项目（HWYX2019011）